Dermatology

A discussion with Dr. Lal on the successful trials and recent approval of dupilumab as a treatment for skin inflammation.

Data indicates a greater number of physicians is a better predictor of melanoma diagnoses than UV radiation rates.

A study finds delayed puberty, a comorbidity of epidermolysis bullosa, may affect skeletal health.

The FDA recently approved a drug treatment for prurigo nodularis, studied across over 60 clinical trials.

A review examined the ways in which costs can be reduced for patients with varying types of atopic dermatitis.

The treatment resulted in significant improvements in the Eczema Area and Severity Index (EASI) scores and patient-reported outcome measure scores.

Research suggests that tildrakizumab may be useful in real-life settings against moderate-to-severe plaque psoriasis.

Research finds potential benefits to using apremilast for plaque psoriasis patients.

A discussion on research into allergic contact dermatitis and its connection to allergens in skincare products.

The results of two phase 3 clinical trials suggest a topical psoriasis treatment option.

New EADV data suggest clinicians may need to uniquely treat patients with adult-onset eczema based on inflammatory pathways.

There is a high risk for contact dermatitis in retail products for skincare, due to the prevalence of allergens.

Research shown at EADV 2022 demonstrated the efficacy of an antibody designed to protect against inflammatory skin disorders.

Research from a double-blind trial suggests a lack of need for clinicians to implement glutamine therapy for burn victims.

The novel OX40 inhibitor molecule showed significant benefit for patients in new EADV 2022 data. A lead author discusses its potential.

The daily TYK2 inhibitor agent was associated with improved rates of psoriasis surface improvement versus apremilast in clinical trials.

New research presented at EADV 2022 suggests positive results for a new JAK1-selective inhibitor for hidradenitis suppurativa.

The Icahn investigator discusses her team's new EADV 2022 data on the JAK inhibitor.

A pair of phase 3 clinical trials presented at EADV 2022 indicate dupilumab significantly improves PN symptoms over 24 weeks.

DaxibotulinumtoxinA-lanm (Daxxify) is the first and only neuromodulator stabilized with Peptide Exchange Technology (PXT) and addresses the treatment duration effect.

Large numbers of vitiligo patients around the world have reported differing outcomes, with darker skin types expressing the more significant severity, according to new findings.

Research presented at EADV 2022 sees positive outcomes with the targeted therapy for patients of varied backgrounds with vitiligo.

Recent research from the National Psoriasis Foundation (NPF) found that 1 in 3 individuals living with psoriatic conditions experience depression.

The latest indications for the novel selective antibody will make it available as a treatment for pustular psoriasis.

A study from Germany elucidated new information on the rare uncombable hair syndrome, changing the ways in which the syndrome may be analyzed.